Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review.
Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review.
复制标题
DOI：
10.1136/rmdopen-2021-001580
复制
发表时间：
2021-05
期刊：
影响因子：
6.2
通讯作者：
Samavati L
中科院分区：
文献类型：
--
作者：
Taha M;Samavati L
许多研究报告了抗磷脂抗体（aPL）在COVID-19患者中的高患病率，这引发了对其真实患病率及其对疾病进程的临床影响的质疑。我们进行了一项荟萃分析和一项系统性综述，以检查aPL的患病率及其对COVID-19患者的临床影响。我们的荟萃分析纳入了21项研究，共1159例患者。在因COVID-19住院的患者中，一种或多种aPL（抗心磷脂（aCL）或抗β 2糖蛋白（抗β 2 GPI）或抗磷脂酰丝氨酸/凝血酶原或狼疮抗凝剂（LA）的IgM或IgG或伊加）的汇总患病率为46.8%（95% CI 36.1%至57.8%）。最常见的aPL类型是LA，合并患病率为50.7%（95% CI 34.8%至66.5%）。与非重症患者相比，COVID-19重症患者的aCL（IgM或IgG）（28.8% vs 7.10%，p<0.0001）和抗β 2 GPI（IgM或IgG）（12.0% vs 5.8%，p<0.0001）患病率显著更高。然而，aPL阳性与C反应蛋白的平均水平之间没有关联，（平均差异为32（95%CI-15至79），p=0.18），D-二聚体（平均差异为34（95% CI-194至273），p=0.77），死亡率（1.46（95% CI 0.29至7.29），p=0.65）、有创通气（1.22（95% CI 0.51至2.91），p=0.65）和静脉血栓栓塞（1.38（95% CI 0.57至3.37），p=0.48）。在近一半的COVID-19患者中检测到aPL，并且在严重疾病中发现aPL的患病率较高。然而，aPL阳性与包括血栓形成、有创通气和死亡率在内的疾病结局之间没有相关性。然而，还需要进一步的研究来确定aPL在COVID-19中的临床和病理作用。
Many studies reported high prevalence of antiphospholipid antibodies (aPL) in patients with COVID-19 raising questions about its true prevalence and its clinical impact on the disease course. We conducted a meta-analysis and a systematic review to examine the prevalence of aPL and its clinical impact in patients with COVID-19. 21 studies with a total of 1159 patients were included in our meta-analysis. Among patients hospitalised with COVID-19, the pooled prevalence rate of one or more aPL (IgM or IgG or IgA of anticardiolipin (aCL) or anti-ß2 glycoprotein (anti-ß2 GPI) or antiphosphatidylserine/prothrombin, or lupus anticoagulant (LA)) was 46.8% (95% CI 36.1% to 57.8%). The most frequent type of aPL found was LA, with pooled prevalence rate of 50.7% (95% CI 34.8% to 66.5%). Critically ill patients with COVID-19 had significantly higher prevalence of aCL (IgM or IgG) (28.8% vs 7.10%, p<0.0001) and anti-ß2 GPI (IgM or IgG) (12.0% vs 5.8%, p<0.0001) as compared with non-critically ill patients. However, there was no association between aPL positivity and mean levels of C reactive protein (mean difference was 32 (95% CI −15 to 79), p=0.18), D-dimer (mean difference was 34 (95% CI −194 to 273), p=0.77), mortality (1.46 (95% CI 0.29 to 7.29), p=0.65), invasive ventilation (1.22 (95% CI 0.51 to 2.91), p=0.65) and venous thromboembolism (1.38 (95% CI 0.57 to 3.37), p=0.48). aPLs were detected in nearly half of patients with COVID-19, and higher prevalence of aPL was found in severe disease. However, there was no association between aPL positivity and disease outcomes including thrombosis, invasive ventilation and mortality. However, further studies are required to identify the clinical and pathological role of aPL in COVID-19.
登录
查看更多内容
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
10.1111/cts.12908
发表时间：
2021-03
期刊：
Clinical and translational science
影响因子：
--
作者：
Pascolini S;Vannini A;Deleonardi G;Ciordinik M;Sensoli A;Carletti I;Veronesi L;Ricci C;Pronesti A;Mazzanti L;Grondona A;Silvestri T;Zanuso S;Mazzolini M;Lalanne C;Quarneti C;Fusconi M;Giostra F;Granito A;Muratori L;Lenzi M;Muratori P
通讯作者：
Muratori P
影响因子：
5.4
作者：
Ferrari E;Sartre B;Squara F;Contenti J;Occelli C;Lemoel F;Levraut J;Doyen D;Dellamonica J;Mondain V;Chirio D;Risso K;Cua E;Orban JC;Ichai C;Labbaoui M;Mossaz B;Moceri P;Appert-Flory A;Fischer F;Toulon P
通讯作者：
Toulon P
DOI：
10.1111/jth.14849
发表时间：
2020-07
期刊：
Journal of thrombosis and haemostasis : JTH
影响因子：
--
作者：
通讯作者：
--
影响因子：
3.4
作者：
Fan, Siyuan;Xiao, Meng;Guan, Hongzhi
通讯作者：
Guan, Hongzhi